<DOC>
	<DOCNO>NCT01224691</DOCNO>
	<brief_summary>Background : - Human respiratory syncytial virus ( RSV ) virus cause respiratory tract infection , frequently responsible hospital visit infant child . It also trigger severe breathe problem individual asthma , infection generally well tolerate non-asthmatics . Some research suggest lack efficient immune system response people asthma may make difficult body fight effect RSV . - Transforming Growth Factor-beta ( TGF- [ beta ] ) chemical body prevalent lung people asthma related respiratory disorder . More information need effect TGF- [ beta ] whether make individual asthma prone develop RSV . Researchers hope use information determine possible treatment therapy individual asthma contract RSV . Objectives : - To determine possible role TGF- [ beta ] increase asthmatic susceptibility RSV infection . Eligibility : - Individuals 18 60 year age either healthy nonsmoker mild asthmatic . Design : - This study involve screen visit study visit . - Participants screen medical history physical examination , well blood sample pulmonary function test . - At study visit , participant receive mild anesthetic bronchoscopy , researcher insert bronchoscope participant nose mouth lung examine lung collect lung cell . - Participants contact research team member 24 36 hour bronchoscopy ask side effect procedure .</brief_summary>
	<brief_title>TGF- ( Beta ) Susceptibility RSV</brief_title>
	<detailed_description>This cross-sectional , control study design investigate whether Transforming Growth Factor-beta ( TGF-beta ) mediate increase asthmatic epithelial susceptibility respiratory syncytial virus ( RSV ) infection examine response RSV infection epithelial cell culture asthmatic non-asthmatic participant . Non-smoking healthy adult mild asthmatic , age 18-60 year old , recruited participate . Potential participant prescreened schedule final eligibility visit include medical history review , vital sign , physical examination , blood draw , pulmonary function test ( PFTs ) . After eligibility confirm , participant schedule bronchoscopy . During bronchoscopy , bronchial epithelium alveolar macrophage obtain participant analysis . Alveolar macrophage evaluate ex-vivo inflammatory activity baseline stimulation . The primary objective laboratory analysis determine TGF-beta mediates increase asthmatic epithelial susceptibility RSV infection . The study three aim interrelate : 1 ) To determine asthmatic bronchial epithelium express TGF-beta normal epithelium ; 2 ) determine RSV replication great asthmatic epithelium normal epithelium ; 3 ) determine TGF-beta mediates asthmatic bronchial epithelial susceptibility RSV infection .</detailed_description>
	<mesh_term>Disease Susceptibility</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Male female 18 60 year age 2 . Nonasthmatics mild asthmatic define : Nonasthmatic must prior diagnosis asthma , history health care utilization medication use asthma , current symptom , Forced Expiratory Volume 1 Second ( FEV1 ) great equal 80 % predict . Asthmatics must physiciandiagnosed asthma least one year evidence mild , persistent disease month prior Visit 1 ( base 2008 GINA guideline ) . ) Participants currently take controller medication must : i. use equivalent GINA Step 1 2 therapy ; ii . control disease , define : daytime symptom less equal 2 time week , wheezing , tightness chest , shortness breath , cough , nocturnal symptom ; b ) Participants currently take controller must : i. &lt; TAB &gt; daytime symptom &gt; 1 time week &lt; 1 time day , wheeze , tightness chest , shortness breath , cough ; ii . nocturnal awakening &gt; 2 time month &lt; 1 time week ; c ) All asthmatic participant must either : i. &lt; TAB &gt; Prebronchdilator FEV1 great equal 80 % predict positive methacholine challenge ( PC20 le equal 4 mg / ml ) ; ii. &lt; TAB &gt; Prebronchodilator FEV1 &lt; 80 % postbronchodilator FEV1 great equal 80 % significant bronchodilator reversibility ( least 12 % 200ml change FEV1 ) 3 . Participants must able understand provide write informed consent 4 . Participants must able travel CRU EPA EXCLUSION CRITERIA : 1 . Use oral steroid treatment ( ) within 30 day Visit 1 2 . Acute asthmarelated healthcare utilization within 30 day Visit 1 , ED visit , systemic corticosteroid , nebulizer treatment asthma exacerbation 3 . Known suspected respiratory infection within 30 day Visit 1 , flu , pneumonia , severe cold , tuberculosis , bronchitis 4 . Known suspected viral infection within 30 day Visit 1 5 . History chronic obstructive pulmonary disease asthma 6 . History immunological disease current cancer 7 . Uncontrolled cardiovascular disease angina , prior myocardial infarction , stroke , high cholesterol 8 . Cardiac malformation 9 . Pulmonary hypertension 10 . Bleeding disorder 11 . Facial deformity , major facial surgery 12 . Currently pregnant breast feed 13 . Current smoker , significant secondhand smoke exposure ( defined urine cotinine &gt; 100 ng/ml Visit 1 Visit 2 ) former smoker ( defined history smoking &gt; 100 cigarette ) 14 . Insulin dependent diabetes 15 . Used follow medication within 30 day Visit 1 : oral corticosteroid , systemic immunosuppressant immunemodifying drug [ e.g. , Rituxan , Humira , Enbrel , Azathioprine ( Imuran ) , Cyclosporine ( Neoral , Sandimmune , SangCya ) , cyclophosphamide , TNF antagonists ] , anticoagulant ( clopidogrel , heparin , enoxaparin related drug , coumadin ) , sustain use ( i.e . one dose per day two day ) nonsteroidal antiinflammatory drug ( aspirin , ibuprofen , indomethacin ) within seven day bronchoscopy 16 . Allergy history adverse reaction methacholine lidocaine 17 . Severe asthma define history intubation unstable asthma 18 . Any condition , investigator 's opinion , place participant undue risk complication ( e.g . PFTs , fiberoptic bronchoscopy , bronchalveolar lavage and/or bronchial brushing ) 19 . Temperature &gt; 37.6 C ; blood pressure &lt; 90/50 mm Hg blood pressure &gt; 170/95 mm Hg ; pulse rate &lt; 50 &gt; 100 beats/minute 20 . Body weight &lt; 50 kg ( &lt; 110 lb ) 21 . The follow abnormal lab value ( value obtain clinical assessment ) : Platelet count &lt; 100,000 per 10 ( 9 ) /L White blood cell count &lt; 3000 per 10 ( 9 ) /L Hematocrit &lt; 35 % female male Prothrombin Time ( PT ) / Abnormal International Normalized Ratio ( INR ) partial prothromboplastin time ( PTT ) base reference laboratory establish reference range Serum creatinine &gt; 1.4 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 5, 2017</verification_date>
	<keyword>Respiratory Syncytial Virus</keyword>
	<keyword>TGF Beta</keyword>
	<keyword>RSV</keyword>
	<keyword>Asthma</keyword>
	<keyword>Healthy Volunteer</keyword>
</DOC>